Exact Sciences/$EXAS
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Exact Sciences
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Ticker
$EXAS
Sector
Primary listing
Employees
6,950
Headquarters
Website
Exact Sciences Metrics
BasicAdvanced
$11B
-
-$5.40
1.05
-
Price and volume
Market cap
$11B
Beta
1.05
52-week high
$70.24
52-week low
$38.81
Average daily volume
2.5M
Financial strength
Current ratio
2.889
Quick ratio
2.322
Long term debt to equity
100.838
Total debt to equity
100.838
Interest coverage (TTM)
-4.84%
Profitability
EBITDA (TTM)
67.114
Gross margin (TTM)
69.63%
Net profit margin (TTM)
-34.19%
Operating margin (TTM)
-4.73%
Effective tax rate (TTM)
0.91%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-1.51%
Return on equity (TTM)
-35.51%
Valuation
Price to revenue (TTM)
3.771
Price to book
4.56
Price to tangible book (TTM)
-13.02
Price to free cash flow (TTM)
65.365
Free cash flow yield (TTM)
1.53%
Free cash flow per share (TTM)
0.91
Growth
Revenue change (TTM)
12.56%
Earnings per share change (TTM)
461.44%
3-year revenue growth (CAGR)
14.89%
10-year revenue growth (CAGR)
70.83%
3-year earnings per share growth (CAGR)
8.48%
10-year earnings per share growth (CAGR)
12.83%
What the Analysts think about Exact Sciences
Analyst ratings (Buy, Hold, Sell) for Exact Sciences stock.
Bulls say / Bears say
Strong Q2 2025 financial performance with 16% revenue growth driven by screening (+18%) and precision oncology (+9%), adjusted EBITDA up 26% to $138 million, and raised full-year guidance (Investing.com)
FDA-approved Cologuard Plus launched March 2025 demonstrates 95% sensitivity and 94% specificity, reducing false positives by 40% and covered by Medicare, enhancing adoption (Verywell Health)
Expanded payer coverage via in-network partnership with Humana making Cologuard Plus available to 5.8 million Medicare Advantage members starting August 2025, supporting volume growth (Investing.com)
Heightened competition after FDA approval of Guardant Health’s Shield blood-based colon cancer test, which detects 83% of cancers in studies compared to Cologuard’s 92.3%, may pressure Exact’s market share (Reuters)
Skepticism over $75 million upfront Freenome licensing deal plus up to $700 million in milestone payments amid concerns about integration and ROI, with analysts warning of ‘throwing good money at bad’ (Investors.com)
Rising operating expenses with SG&A up ~17% YoY and quarterly free cash flow down from $71 million to $47 million, highlighting ongoing investment pressures on profitability (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Exact Sciences Financial Performance
Revenues and expenses
Exact Sciences Earnings Performance
Company profitability
Exact Sciences News
AllArticlesVideos
Exact Sciences Schedules Third Quarter 2025 Earnings Call
Business Wire2 days ago
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
Business Wire3 weeks ago
Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exact Sciences stock?
Exact Sciences (EXAS) has a market cap of $11B as of October 10, 2025.
What is the P/E ratio for Exact Sciences stock?
The price to earnings (P/E) ratio for Exact Sciences (EXAS) stock is 0 as of October 10, 2025.
Does Exact Sciences stock pay dividends?
No, Exact Sciences (EXAS) stock does not pay dividends to its shareholders as of October 10, 2025.
When is the next Exact Sciences dividend payment date?
Exact Sciences (EXAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Exact Sciences?
Exact Sciences (EXAS) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.